Kolneb

Colistimethate Sodium, the active ingredient in Kolneb, is a Polymyxin antibiotic presented as a unknown/unknown for inhalation use. It treats chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

GNH USA supplies Kolneb as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kolneb is a polymyxin antibiotic used to manage chronic Gram‑negative bacterial infections of the respiratory tract.

Cystic fibrosis: reduces chronic Pseudomonas aeruginosa lung infection burden. Non‑cystic fibrosis bronchiectasis: helps control chronic Pseudomonas aeruginosa colonisation. Ventilator‑associated pneumonia: provides adjunctive inhaled therapy against Pseudomonas aeruginosa.

Kolneb may cause a range of respiratory and systemic reactions.

Common Side Effects: - Cough or throat irritation. - Bronchospasm or wheezing. - Dysphonia (hoarse voice). - Nausea or mild gastrointestinal upset. - Headache. - Transient fever.

Serious or Rare Side Effects: - Acute respiratory distress or severe bronchospasm. - Anaphylactic reaction or severe hypersensitivity. - Nephrotoxicity due to systemic absorption. - Neurotoxicity, including paresthesia or seizures. - Hemoptysis. - Persistent or worsening lung infection.

When prescribing Kolneb, clinicians should consider several safety measures.

Monitor renal function: assess for potential nephrotoxicity, especially with prolonged use. Assess for hypersensitivity: discontinue if signs of allergic reaction appear. Use cautiously in pre‑existing lung disease: patients with severe airway hyperreactivity may experience bronchospasm. Avoid concurrent nephrotoxic agents: limit use with aminoglycosides or loop diuretics. Pregnancy and lactation: risk unknown; weigh benefits against potential fetal or infant exposure. Store at room temperature: keep in original container, protect from moisture and light.

Colistimethate Sodium can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: increased risk of renal impairment. - Vancomycin: overlapping nephrotoxic potential. - Nephrotoxic chemotherapeutics (e.g., cisplatin): heightened renal risk. - High‑dose NSAIDs: may exacerbate kidney injury.

Moderate Interactions (Monitor Closely): - Bronchodilators: may provoke bronchospasm when combined. - Systemic corticosteroids: can mask infection signs. - Other inhaled antibiotics: potential additive respiratory toxicity. - Antacids containing magnesium or aluminum: may affect aerosol stability. - Warfarin: monitor INR as infection control may alter coagulation status.